According to the GEN website, Sanofi has signed a cooperation and licensing deal with Exscientia with a potential value of 250 million euros (about 276 million US dollars). The deal aims to develop bispecific small molecule drugs for metabolic diseases.
Exscientia will use its artificial intelligence (AI)-driven platform and automated design capabilities to identify synergistic drug target combinations and then use its lead-finding platform to identify bispecific small targets for these targets. Molecular drugs.
Exscientia will be responsible for all compound designs and Sanofi offers chemical synthesis. In addition, Sanofi retains the option to license "related compounds" and will undertake future preclinical and clinical development. Exscientia will receive research funding for identifying "target pairs" and priority drug candidates and will be eligible for future non-clinical, clinical, and sales-related milestone payments.
Sanofi will use the artificial intelligence to drive the platform to develop bispecific drugs
Exscientia's drug development "engine" is built on an AI platform. Companies can use the platform to design and evaluate new compounds, including potency, selectivity, and ADME. The company is using the platform to build partnerships to develop small molecule drugs for single targets and bispecific small molecule candidates for target combinations.
In addition to this new transaction, in April 2016, Exscientia and Germany Evotec reached an agreement on the Immuno-Oncology. At the AACR annual meeting last month, the two sides published details of selective adenosine 2A receptor antagonists and bispecific small molecule drugs (targeting A2AR and CD73).
In addition, Exscientia's "new partner" Sanofi also has a partnership with Evotec. The two sides have reached a cooperation in 2015, including cooperation in the development of beta-based diabetes therapy.
Shanghai Rocatti Biotechnology Co., Ltd. is a professional enterprise of rehabilitation and medical device products with sales and service as the main body. Since its establishment, the company has been committed to the development of medical devices. Its products involve the production of epidemic prevention materials such as gynecology (obstetrics), Urology, neurosurgery, kn95 medical protective masks, daily use flat masks, and the research and development of total nutrition slimming food. It can provide a complete range of first, second and third class medical device configuration schemes for general hospitals and specialized hospitals.
Nonwoven Face Mask,Non-Woven Facial Face Mask,Non-Woven Face Mask Ffp2,Non-Woven Surgical Face Mask
Shanghai Rocatti Biotechnology Co.,Ltd , https://www.ljdmedicals.com